Drug intelligence / Profile preview

RDH100

Development stage: Preclinical
Lead developer: Apichope Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

RDH100 is an investigational small molecule drug candidate currently in preclinical development by Apichope Pharmaceutical. It is being developed as an injectable therapy for the treatment of neurological system diseases, with a primary focus on acute ischemic stroke and other cerebrovascular conditions. RDH100 is designed to function as a neuroprotective agent, aiming to mitigate the cascade of neuronal damage that occurs during and after an ischemic event. By protecting brain tissue from further injury, the drug seeks to improve functional recovery and long-term outcomes for patients suffering from stroke. As a preclinical asset, its specific molecular target has not yet been publicly disclosed.

Other names: RDH100 injectionRDH-100 injectionRDH 100 injection

Beyond the preview

Go deeper on RDH100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RDH100.

Explore the full profile